Oruka Therapeutics, Inc.
ORKA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $29 | $24 | $20 | $32 |
| G&A Expenses | $5 | $4 | $5 | $6 |
| SG&A Expenses | $5 | $4 | $5 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $34 | $28 | $25 | $38 |
| Operating Income | -$34 | -$28 | -$25 | -$38 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $4 | $4 | $4 | $5 |
| Pre-Tax Income | -$30 | -$25 | -$21 | -$33 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$30 | -$25 | -$21 | -$33 |
| % Margin | – | – | – | – |
| EPS | -0.69 | -0.58 | -0.5 | -1.54 |
| % Growth | -19% | -16% | 67.5% | – |
| EPS Diluted | -0.69 | -0.58 | -0.5 | -1.54 |
| Weighted Avg Shares Out | 44 | 42 | 42 | 17 |
| Weighted Avg Shares Out Dil | 44 | 42 | 42 | 17 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $4 | $4 | $5 |
| Interest Expense | – | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$30 | -$25 | -$21 | -$37 |
| % Margin | – | – | – | – |